Grant Number:	5R01CA095662-04 Interpret this number
Primary Investigator:	Sanda, Martin
Organization:	Beth Israel Deaconess Medical Center
Project Title:	Survivor Qol/Spouse Satisfaction After Prostate Therapy
Fiscal Year:	2005

DESCRIPTION (provided by applicant): Background: Health related quality of life (HRQOL) is a pivotal concern for early stage prostate cancer survivors and their spouses. Recent developments, including the emergence of brachytherapy (BT), the development of 3-D conformal radiotherapy (3D-ERT), the increased use of adjuvant hormonal therapy, and the observation that radical prostatectomy (RP) outcomes may differ between practitioners, fuel a need to re-evaluate HRQOL outcomes in this context. HRQOL following BT, 3D-ERT, and RP have not been characterized with an instrument validated to detect effects of each of these interventions. Moreover, patient or provider determinants of patient HRQOL, patient satisfaction, and spouse satisfaction remain uncharacterized. Because prostate cancer survivors and experts determined that existing HRQOL instruments lacked key items for concurrently evaluating HRQOL effects of BT, ERT, and RP, we developed and validated the Expanded Prostate Cancer Index Composite (EPIC) instrument using a cohort that equally represented each of these 3 interventions. Factor analysis revealed 2 new HRQOL domains (urinary-irritative and hormonal) complementing the 3 function domains of UCLA-PCI (urinary-incontinence, bowel, sexual). The 5 HRQOL domains measured by EPIC showed satisfactory internal consistency, reliability, and external validity. Cross-sectional HRQOL comparison among 1014 BT, 3D-ERT, or RP survivors and controls showed that each EPIC HRQOL domain was adversely affected by at least one of the therapies. EPIC HRQOL domain scores associated significantly with patient satisfaction and were sensitive to baseline factors such as age, cancer severity, and prostate size. We hypothesize that patient and provider characteristics affect HRQOL changes after brachytherapy, external radiation, or prostatectomy, and that these interventions have different HRQOL effects, which impact long-term patient and spouse satisfaction. The proposed observational study has the following Specific Aims: 1) To assess baseline determinants, including provider characteristics, of long-term HRQOL after BT, 3D-ERT, or RP; 2) To characterize baseline determinants of patient and spouse satisfaction with intervention process and outcome; and 3) To evaluate effects of therapy choice on HRQOL outcome and satisfaction. Experimental Design: A prospective, observational, multi-institutional study will be performed at 5 institutions with pre-existing, multi-disciplinary expertise in BT, 3D-ERT, and RP. Patients with early stage prostate cancer electing to undergo BT, 3D-ERT, or RP as primary therapy will be eligible. Baseline demographics, cancer severity measures, and provider characteristics will be recorded, while HRQOL will be measured using the EPIC survey instrument administered at baseline (pre-therapy); then at 2 months, 6 months, and yearly after therapy for 3 years. The multidimensional SSS-10 instrument, administered to survivors and their spouses or life partners, will measure satisfaction with process and outcome. The principal endpoints will be changes in EPIC domain summary scores from baseline to two years after therapy, and survivor satisfaction as well as spouse satisfaction. For each procedure, HRQOL changes over time and yearly satisfaction scores will be modeled by a mixed effects model; baseline risk factors that affect change will be identified. The effects of each therapy on change in HRQOL will be compared after controlling for risk factors identified in the previous step. The findings from this prospective, observational study will provide benchmarks to guide outcomes expectations and to facilitate evidence-based decisions regarding therapy.




Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.
Authors: Chang P. , Wagner A.A. , Regan M.M. , Smith J.A. , Saigal C.S. , Litwin M.S. , Hu J.C. , Cooperberg M.R. , Carroll P.R. , Klein E.A. , et al. .
Source: The Journal Of Urology, 2022 Jan; 207(1), p. 127-136.
EPub date: 2021-08-26 00:00:00.0.
PMID: 34433304
Related Citations

External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
Authors: Gay H.A. , Sanda M.G. , Liu J. , Wu N. , Hamstra D.A. , Wei J.T. , Dunn R.L. , Klein E.A. , Sandler H.M. , Saigal C.S. , et al. .
Source: International Journal Of Radiation Oncology, Biology, Physics, 2017-06-01 00:00:00.0; 98(2), p. 304-317.
EPub date: 2017-02-22 00:00:00.0.
PMID: 28463150
Related Citations

Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment.
Authors: Chang P. , Regan M.M. , Ferrer M. , Guedea F. , Patil D. , Wei J.T. , Hembroff L.A. , Michalski J.M. , Saigal C.S. , Litwin M.S. , et al. .
Source: The Journal Of Urology, 2017 Feb; 197(2), p. 376-384.
PMID: 27593476
Related Citations

Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
Authors: Evans J.R. , Zhao S. , Daignault S. , Sanda M.G. , Michalski J. , Sandler H.M. , Kuban D.A. , Ciezki J. , Kaplan I.D. , Zietman A.L. , et al. .
Source: Radiotherapy And Oncology : Journal Of The European Society For Therapeutic Radiology And Oncology, 2015 Aug; 116(2), p. 179-84.
PMID: 26276528
Related Citations

Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form.
Authors: Skolarus T.A. , Dunn R.L. , Sanda M.G. , Chang P. , Greenfield T.K. , Litwin M.S. , Wei J.T. , PROSTQA Consortium .
Source: Urology, 2015 Jan; 85(1), p. 101-5.
PMID: 25530370
Related Citations

Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment.
Authors: Storås A.H. , Sanda M.G. , Ferrer M. , Loge J.H. , Dahl A.A. , Steinsvik E.A. , Guedea F. , Cvancarova M. , Fosså S.D. .
Source: Clinical Genitourinary Cancer, 2014 Aug; 12(4), p. e117-25.
PMID: 24524968
Related Citations

Satisfaction with information used to choose prostate cancer treatment.
Authors: Gilbert S.M. , Sanda M.G. , Dunn R.L. , Greenfield T.K. , Hembroff L. , Klein E. , Saigal C.S. , Pisters L. , Michalski J. , Sandler H.M. , et al. .
Source: The Journal Of Urology, 2014 May; 191(5), p. 1265-71.
PMID: 24333514
Related Citations

Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.
Authors: Hoppe B.S. , Michalski J.M. , Mendenhall N.P. , Morris C.G. , Henderson R.H. , Nichols R.C. , Mendenhall W.M. , Williams C.R. , Regan M.M. , Chipman J.J. , et al. .
Source: Cancer, 2014-04-01 00:00:00.0; 120(7), p. 1076-82.
EPub date: 2014-04-01 00:00:00.0.
PMID: 24382757
Related Citations

Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice.
Authors: Chipman J.J. , Sanda M.G. , Dunn R.L. , Wei J.T. , Litwin M.S. , Crociani C.M. , Regan M.M. , Chang P. , PROST-QA Consortium .
Source: The Journal Of Urology, 2014 Mar; 191(3), p. 638-45.
PMID: 24076307
Related Citations

Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study.
Authors: Gay H.A. , Michalski J.M. , Hamstra D.A. , Wei J.T. , Dunn R.L. , Klein E.A. , Sandler H.M. , Saigal C. , Litwin M. , Kuban D. , et al. .
Source: Urology, 2013 Dec; 82(6), p. 1363-8.
PMID: 24139340
Related Citations

Survivorship after prostate cancer treatment: spouses' quality of life at 36 months.
Authors: Harden J. , Sanda M.G. , Wei J.T. , Yarandi H.N. , Hembroff L. , Hardy J. , Northouse L. .
Source: Oncology Nursing Forum, 2013 Nov; 40(6), p. 567-73.
PMID: 24161635
Related Citations

Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience.
Authors: Hamstra D.A. , Conlon A.S. , Daignault S. , Dunn R.L. , Sandler H.M. , Hembroff A.L. , Zietman A.L. , Kaplan I. , Ciezki J. , Kuban D.A. , et al. .
Source: International Journal Of Radiation Oncology, Biology, Physics, 2013-07-01 00:00:00.0; 86(3), p. 546-53.
EPub date: 2013-07-01 00:00:00.0.
PMID: 23561651
Related Citations

Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.
Authors: Gray P.J. , Paly J.J. , Yeap B.Y. , Sanda M.G. , Sandler H.M. , Michalski J.M. , Talcott J.A. , Coen J.J. , Hamstra D.A. , Shipley W.U. , et al. .
Source: Cancer, 2013-05-01 00:00:00.0; 119(9), p. 1729-35.
EPub date: 2013-05-01 00:00:00.0.
PMID: 23436283
Related Citations

Partners' long-term appraisal of their caregiving experience, marital satisfaction, sexual satisfaction, and quality of life 2 years after prostate cancer treatment.
Authors: Harden J.K. , Sanda M.G. , Wei J.T. , Yarandi H. , Hembroff L. , Hardy J. , Northouse L.L. , PROSTQA Consortium Study Group .
Source: Cancer Nursing, 2013 Mar-Apr; 36(2), p. 104-13.
PMID: 22728952
Related Citations

Uncertainty and perception of danger among patients undergoing treatment for prostate cancer.
Authors: Kazer M.W. , Bailey D.E. , Chipman J. , Psutka S.P. , Hardy J. , Hembroff L. , Regan M. , Dunn R.L. , Crociani C. , Sanda M.G. , et al. .
Source: Bju International, 2013 Mar; 111(3 Pt B), p. E84-91.
PMID: 22985348
Related Citations

Prediction of erectile function following treatment for prostate cancer.
Authors: Alemozaffar M. , Regan M.M. , Cooperberg M.R. , Wei J.T. , Michalski J.M. , Sandler H.M. , Hembroff L. , Sadetsky N. , Saigal C.S. , Litwin M.S. , et al. .
Source: Jama, 2011-09-21 00:00:00.0; 306(11), p. 1205-14.
PMID: 21934053
Related Citations

Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.
Authors: Chang P. , Szymanski K.M. , Dunn R.L. , Chipman J.J. , Litwin M.S. , Nguyen P.L. , Sweeney C.J. , Cook R. , Wagner A.A. , DeWolf W.C. , et al. .
Source: The Journal Of Urology, 2011 Sep; 186(3), p. 865-72.
PMID: 21788038
Related Citations

The experiences of unpartnered men with prostate cancer: a qualitative analysis.
Authors: Kazer M.W. , Harden J. , Burke M. , Sanda M.G. , Hardy J. , Bailey D.E. , PROSTQA Study Group .
Source: Journal Of Cancer Survivorship : Research And Practice, 2011 Jun; 5(2), p. 132-41.
PMID: 21113818
Related Citations

Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet.
Authors: Kamo N. , Dandapani S.V. , Miksad R.A. , Houlihan M.J. , Kaplan I. , Regan M. , Greenfield T.K. , Sanda M.G. .
Source: Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / Esmo, 2011 Mar; 22(3), p. 723-9.
PMID: 20716625
Related Citations

Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
Authors: Szymanski K.M. , Wei J.T. , Dunn R.L. , Sanda M.G. .
Source: Urology, 2010 Nov; 76(5), p. 1245-50.
PMID: 20350762
Related Citations

Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study.
Authors: Sandler H.M. , Liu P.Y. , Dunn R.L. , Khan D.C. , Tropper S.E. , Sanda M.G. , Mantz C.A. .
Source: Urology, 2010 May; 75(5), p. 1004-8.
PMID: 20153881
Related Citations

Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.
Authors: Shappley W.V. , Kenfield S.A. , Kasperzyk J.L. , Qiu W. , Stampfer M.J. , Sanda M.G. , Chan J.M. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2009-10-20 00:00:00.0; 27(30), p. 4980-5.
EPub date: 2009-10-20 00:00:00.0.
PMID: 19720918
Related Citations

A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment.
Authors: Sanda M.G. , Kaplan I.D. .
Source: Jama, 2009-05-27 00:00:00.0; 301(20), p. 2141-51.
EPub date: 2009-05-27 00:00:00.0.
PMID: 19417179
Related Citations

A safety-modified SV40 Tag developed for human cancer immunotherapy.
Authors: Tseng-Rogenski S.S. , Arredouani M.S. , Escara-Wilke J.F. , Neeley Y.C. , Imperiale M.J. , Sanda M.G. .
Source: Drug Design, Development And Therapy, 2009-02-06 00:00:00.0; 2, p. 17-24.
EPub date: 2009-02-06 00:00:00.0.
PMID: 19920890
Related Citations

Quality of life and satisfaction with outcome among prostate-cancer survivors.
Authors: Sanda M.G. , Dunn R.L. , Michalski J. , Sandler H.M. , Northouse L. , Hembroff L. , Lin X. , Greenfield T.K. , Litwin M.S. , Saigal C.S. , et al. .
Source: The New England Journal Of Medicine, 2008-03-20 00:00:00.0; 358(12), p. 1250-61.
PMID: 18354103
Related Citations

Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer.
Authors: Dandapani S.V. , Sanda M.G. .
Source: Seminars In Radiation Oncology, 2008 Jan; 18(1), p. 67-72.
PMID: 18082590
Related Citations

Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy.
Authors: Symon Z. , Daignault S. , Symon R. , Dunn R.L. , Sanda M.G. , Sandler H.M. .
Source: Urology, 2006 Dec; 68(6), p. 1224-9.
PMID: 17141840
Related Citations

Medical therapy to facilitate urinary stone passage: a meta-analysis.
Authors: Hollingsworth J.M. , Rogers M.A. , Kaufman S.R. , Bradford T.J. , Saint S. , Wei J.T. , Hollenbeck B.K. .
Source: Lancet (london, England), 2006-09-30 00:00:00.0; 368(9542), p. 1171-9.
PMID: 17011944
Related Citations

Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy.
Authors: Montgomery J.S. , Gayed B.A. , Hollenbeck B.K. , Daignault S. , Sanda M.G. , Montie J.E. , Wei J.T. .
Source: The Journal Of Urology, 2006 Jul; 176(1), p. 257-61; discussion 261-2.
PMID: 16753415
Related Citations

Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference.
Authors: Miller D.C. , Wei J.T. , Dunn R.L. , Montie J.E. , Pimentel H. , Sandler H.M. , McLaughlin P.W. , Sanda M.G. .
Source: Urology, 2006 Jul; 68(1), p. 166-71.
PMID: 16844457
Related Citations

Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
Authors: Miller D.C. , Sanda M.G. , Dunn R.L. , Montie J.E. , Pimentel H. , Sandler H.M. , McLaughlin W.P. , Wei J.T. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2005-04-20 00:00:00.0; 23(12), p. 2772-80.
PMID: 15837992
Related Citations

Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling.
Authors: Dash A. , Dunn R.L. , Resh J. , Wei J.T. , Montie J.E. , Sanda M.G. .
Source: Urology, 2004 Jul; 64(1), p. 117-22.
PMID: 15245947
Related Citations

Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer.
Authors: Hollenbeck B.K. , Wei J.T. , Sanda M.G. , Dunn R.L. , Sandler H.M. .
Source: Urology, 2004 May; 63(5), p. 946-50.
PMID: 15134986
Related Citations

Racial/ethnic disparities in the treatment of localized/regional prostate cancer.
Authors: Underwood W. , De Monner S. , Ubel P. , Fagerlin A. , Sanda M.G. , Wei J.T. .
Source: The Journal Of Urology, 2004 Apr; 171(4), p. 1504-7.
PMID: 15017208
Related Citations

Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
Authors: Nelson C.P. , Dunn R.L. , Wei J.T. , Rubin M.A. , Montie J.E. , Sanda M.G. .
Source: Urologic Oncology, 2003 May-Jun; 21(3), p. 213-8.
PMID: 12810209
Related Citations

Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument.
Authors: Hollenbeck B.K. , Dunn R.L. , Wei J.T. , Montie J.E. , Sanda M.G. .
Source: The Journal Of Urology, 2003 Apr; 169(4), p. 1453-7.
PMID: 12629382
Related Citations